cbd oil follicular lymphoma

December 15, 2021 By admin Off

Until today (1 November 2018), medicinal cannabis was only available in very specific circumstances and required doctors to apply for a special licence. Following a recent Government review, medicinal cannabis can now be prescribed by specialist doctors for conditions for which there is clear published evidence of its benefit for people who have no other licensed treatment option. This includes adults with nausea or vomiting caused by chemotherapy who have not responded to any licensed treatments. The decision to prescribe cannabis-based products for medicinal use must be made by a specialist doctor – not a GP – and will be made on a case-by-case basis.

For the first time in the UK, medicinal cannabis can be prescribed for adults with chemotherapy-related nausea and vomiting who have not responded to other treatments without the need for a special licence.

Medicinal cannabis can now be prescribed for adults with chemotherapy-related nausea or vomiting, who haven’t responded to licensed treatment.

The government review did not reclassify the legal status of cannabis. It is illegal to take, carry, grow or sell cannabis in the UK. Home-grown cannabis and cannabis bought illegally contain many active chemicals in unpredictable amounts. It is not safe to use instead of medicinal cannabis.

Hodgkin lymphoma (HL) is one of the most curable malignancies. Despite its effectiveness, chemotherapy is often associated with adverse events (AEs) such as nausea, anorexia, and impairment of general well-being. Our objective was to assess the extent of medical cannabis use among HL patients and evaluate its efficacy in controlling chemotherapy-related AEs. Patterns of medical cannabis use and efficacy were evaluated using physician-completed application forms, medical files, and patient-completed questionnaires, for all consecutive adult HL patients treated at the Tel-Aviv Medical Center between June 2010 and November 2016. One-hundred and thirty-three patients met the inclusion criteria. The median age of the cohort was 37 years, 53% were male, 46% were diagnosed at an early stage, and 88% achieved a complete response to treatment. Fifty-one patients (38%) used medical cannabis. There were no significant differences in baseline characteristics between cannabis users and nonusers. Cannabis users reported improvement in pain, general well-being, appetite, and nausea in 94, 87, 82, and 79% of cases, respectively. Importantly, 81.5% reported a high overall efficacy of cannabis in relieving symptoms. AEs related to cannabis use itself were mild. Thus, medical cannabis use is prevalent in this HL cohort, and appears to be effective in ameliorating chemotherapy-related AEs.

Keywords: Cannabis; Chemotherapy-related adverse events; Hodgkin lymphoma.

Further evidence from randomised controlled trials is required to evaluate the impact of cannabis and cannabinoid products on cancer and side effects of chemotherapy. There are currently a number of trials underway in Australia reviewing the potential benefits of cannabis and its efficacy for use across different medical indications.

Cannabis and cannabinoids are derived from the Cannabis sativa plant. Cannabis, also known as marijuana (and colloquially as grass, pot, weed, hash etc.), is made from the dried flowers and leaves of the Cannabis sativa plant. Cannabinoids are chemicals which act upon cannabinoid receptors, CB1 and CB2 in the body.

The majority of available evidence for the therapeutic use of cannabis and cannabinoids in cancer care addresses their potential efficacy in relieving the symptoms of cancer and cancer treatments such as chemotherapy. The effects of cannabis and cannabinoids can differ significantly with different doses and between individuals, and can vary depending on how cannabis compounds enter the body.

The potential benefits of cannabis and cannabinoids (active compounds derived from the cannabis plant) for symptom relief in cancer patients have been subject to a number of government reviews and public debate in recent years. Governments at Commonwealth, state and territory levels have made legislative and policy changes to progress access and investigation of cannabis in the treatment of various medical indications. However, there are currently no natural and synthetic forms of cannabis and cannabinoids products approved in Australia for therapeutic use to alleviate side effects of cancer and chemotherapy.

Applications to access unapproved cannabis-based therapeutic products must be considered through the Commonwealth Department of Health special access programs and processed on a case by case basis and are subject to state-based requirements as well as import legislation.

The Therapeutic Goods Administration (TGA) recently released a set of guidances to assist health professionals and patients, especially medical practitioners, who choose to prescribe medicinal cannabis in Australia under current access schemes. These are available on the TGA website.